NCT03580278View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

September 22, 2020

Study Completion Date

September 22, 2020

Conditions
Psoriasis
Interventions
BIOLOGICAL

ABY-035/AFO2

Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis

Trial Locations (1)

16133

Raoof, Joseph, Encino

Sponsors

Lead Sponsor

Affibody
All Listed Sponsors
lead

Affibody

INDUSTRY